Security key
87164U508
Theriva Biologics, Inc. - Common stock (TOVX)
CUSIP: 87164U508
Q3 2026 13F Holders as of 30 Sep 2026
- Security type / class
- Equity / Common stock
- Total 13F shares
- 1,099
- Total 13F value
- $247
- Share change
- +725
- SEC-reported price per share
- $0.20
- Number of holders
- 3
- Value change
- +$163
- Number of buys
- 1
- Shares outstanding
- 9,600,143
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2026
Institutions
3
Top holders
3
TOVX full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q2 2026
Theriva Biologics, Inc. SEC filings
Theriva Biologics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 87164U508
Recent filing periods:
Ownership snapshot
Top reported holders of TOVX - Theriva Biologics, Inc. - Common stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Jeffrey Matthew Gryga Irr...
Disclosed value leader
Jeffrey Matthew Gryga Irr...
Comparable rows
3/15
Latest evidence
30 Jun 2026
13D/G
13F
Lead comparable stake: 7.7%
12 rows are not safely comparable across share classes.
13D/G row: Jeffrey Matthew Gryga Irrevocable Trust
Showing 1-6 of 15 holder rows.
Quick read
Jeffrey Matthew Gryga Irrevocable Trust leads the comparable SEC ownership view at 7.7%.
3 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Jeffrey Matthew Gryga Irrevocable Trust's linked filing trail.
Comparable ownership
Top 3
Jeffrey Matthew Gryga Irrevocable...
7.7%
Empery Asset Management, LP
5%
CVI Investments, Inc.
4.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Jeffrey Matthew Gryga Irrevocable Trust |
13D/G
|
7.7%
Reported 13D/G
· 24 Oct 2025
|
$300,046
739,211 shares
|
$0 | 24 Oct 2025 |
| Empery Asset Management, LP |
13D/G
|
5%
Reported 13D/G
· 30 Sep 2025
|
$201,636
504,091 shares
|
-$179,638 | 30 Sep 2025 |
| CVI Investments, Inc. |
13D/G
|
4.9%
Reported 13D/G
· 31 Dec 2024
|
$206,052
146,136 shares
|
$0 | 31 Dec 2024 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
—
denominator unverified
|
$121,545
486,179 shares
|
— | 30 Jun 2026 |
| JANE STREET GROUP, LLC |
13F
Company
|
—
denominator unverified
|
$83,047
331,922 shares
|
— | 30 Jun 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
—
denominator unverified
|
$73,563
294,021 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
3
Shares
1,099
Rows available
3
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2026 vs Q2 2026 Across Filers
Q2 2026 holders
24
Q3 2026 holders
3
Holder diff
-21
| Investor | Q2 2026 Shares | Q3 2026 Shares | Share Diff | Share Chg % | Q2 2026 value | Q3 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend